01—Abstract
Summary
Summary of the 8-K filed May 28, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with 90,118,625 of 100,581,991 eligible shares (record date March 31, 2026) present in person or by proxy.
Stockholders elected three Class III Directors to terms expiring at the 2029 Annual Meeting: Kevin C. Gorman, Ph.D. (76,228,063 votes for), Gary A.
Lyons (75,278,705 votes for), and Johanna Mercier (74,671,942 votes for). Continuing directors are William H. Rastetter, Ph.D., George J.
Morrow, Leslie V. Norwalk, and Christine A. Poon (Class I, term expiring 2027), and Kyle W.
Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D.
(Class II, term expiring 2028). Stockholders also approved, on an advisory basis, the compensation paid to the company's named executive officers (78,993,894 for, 5,669,155 against, 103,231 abstentions). They approved the amendment of the 2025 Equity Incentive Plan (the "Amended 2025 Plan") with 79,131,622 votes for and 5,568,926 against.
A summary of the Amended 2025 Plan's material terms appears in the definitive proxy statement filed April 15, 2026, which is incorporated by reference. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,880,185 votes for and 6,170,483 against. This filing reports routine annual meeting outcomes, with no material change to officers or directors disclosed.
02—Key points
Key Highlights
- Annual Meeting held May 27, 2026; 90,118,625 of 100,581,991 eligible shares were present in person or by proxy
- All three Class III director nominees elected to terms expiring at the 2029 Annual Meeting: Kevin C. Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier
- Stockholders approved the amendment of the 2025 Equity Incentive Plan (Amended 2025 Plan), with 79,131,622 votes for and 5,568,926 against
- Advisory say-on-pay proposal approved: 78,993,894 votes for and 5,669,155 against
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026 (83,880,185 for, 6,170,483 against)
- Amended 2025 Plan terms are detailed in the April 15, 2026 definitive proxy statement, incorporated by reference
03—Questions
Frequently Asked Questions
Who was elected to the Board of Directors at the 2026 Annual Meeting?
Kevin C. Gorman, Ph.D. (76,228,063 votes for), Gary A. Lyons (75,278,705 votes for), and Johanna Mercier (74,671,942 votes for) were elected as Class III Directors for three-year terms expiring at the 2029 Annual Meeting. Each nominee had 5,352,345 broker non-votes.
What did stockholders approve regarding the equity incentive plan?
Stockholders approved an amendment to the 2025 Equity Incentive Plan, with 79,131,622 votes for, 5,568,926 against, 65,732 abstentions, and 5,352,345 broker non-votes. A summary of the plan's material terms is in the proxy statement filed April 15, 2026.
How did stockholders vote on executive compensation?
In a non-binding advisory vote, stockholders approved the compensation paid to the named executive officers, with 78,993,894 votes for, 5,669,155 against, 103,231 abstentions, and 5,352,345 broker non-votes.
Which accounting firm was ratified for the current fiscal year?
Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,880,185 votes for, 6,170,483 against, and 67,957 abstentions.
04—Continue